Profile data is unavailable for this security.
About the company
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
- Revenue in EUR (TTM)3.57m
- Net income in EUR-17.36m
- Incorporated1996
- Employees11.00
- LocationNicox SADrakkar 2 - Batiment D2405 route des DolinesCS 10313 Sophia AntipolisVALBONNE 06560FranceFRA
- Phone+33 497245300
- Fax+33 497245399
- Websitehttp://www.nicox.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hybrigenics SA | 0.00 | -69.16k | 4.00m | 17.00 | -- | 0.2742 | -- | -- | -0.0003 | -0.0003 | 0.00 | 0.0361 | 0.00 | -- | -- | -- | -0.7067 | -35.48 | -0.877 | -48.94 | -- | -- | -- | -5,115.72 | -- | -- | 0.1032 | -- | 100.00 | -- | 78.83 | -- | -- | -- |
Medesis Pharma SA | 0.00 | -2.79m | 4.03m | 10.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.5862 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.14 | -23.17 | -- | -- | -100.00 | -- | -3.87 | -- | -- | -- |
IntegraGen SA | 12.49m | -123.83k | 4.27m | 57.00 | -- | 2.20 | 52.43 | 0.342 | -0.0179 | -0.0179 | 1.88 | 0.2887 | 1.24 | 9.09 | 3.09 | 198,274.60 | -1.23 | -4.20 | -4.00 | -9.43 | 64.75 | 64.10 | -0.9913 | -3.67 | 1.23 | -- | 0.418 | -- | 16.27 | 16.08 | -122.78 | -- | -- | -- |
Theranexus SA | 0.00 | -6.83m | 7.37m | 19.00 | -- | 3.32 | -- | -- | -1.09 | -1.09 | 0.00 | 0.2863 | 0.00 | -- | -- | 0.00 | -70.79 | -42.66 | -82.29 | -47.97 | -- | -- | -- | -- | -- | -1,058.68 | 0.6212 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
Quantum Genomics SA | 10.06k | -3.17m | 7.74m | 3.00 | -- | 8.86 | -- | 769.17 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
Acticor Biotech SA | 0.00 | -18.65m | 10.75m | 24.00 | -- | 22.87 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
NicOx SA | 3.57m | -17.36m | 13.35m | 11.00 | -- | 0.2909 | -- | 3.74 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
Ikonisys SA | 538.56k | -2.40m | 15.19m | 11.00 | -- | 0.8235 | -- | 28.21 | -0.2499 | -0.2499 | 0.056 | 1.75 | 0.0246 | 1.14 | 6.20 | 48,960.00 | -10.94 | -- | -12.55 | -- | 2.72 | -- | -444.76 | -- | 0.0818 | -36.79 | 0.1007 | -- | 68.94 | -- | -328.57 | -- | -- | -- |
Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 15.53m | 56.00 | 193.24 | 1.81 | 26.78 | 9.23 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | -- | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
Valerio Therapeutics SA | 1.80m | -20.34m | 16.05m | 19.00 | -- | 1.08 | -- | 8.92 | -0.1566 | -0.1566 | 0.0133 | 0.0961 | 0.0459 | -- | 1.07 | 94,736.84 | -51.92 | -34.19 | -67.72 | -40.59 | 70.39 | 84.11 | -1,130.22 | -586.99 | -- | -171.66 | 0.3776 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
Nfl Biosciences SAS | 0.00 | -3.48m | 19.99m | 3.00 | -- | 5.03 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 20.01m | 22.00 | -- | 4.96 | -- | 18.66 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2023 | 2.72m | 5.41% |
Erasmus Gestion SASas of 31 May 2024 | 190.00k | 0.38% |
Gestys SAas of 26 Jan 2024 | 60.00k | 0.12% |
Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 43.30k | 0.09% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 0.00 | 0.00% |
Financi�re Arbevel SAas of 30 Jun 2021 | 0.00 | 0.00% |
Apo Asset Management GmbHas of 30 Sep 2023 | 0.00 | 0.00% |